DNA polymerase beta participates in DNA End-joining

por Ray, Sreerupa, Breuer, Gregory, DeVeaux, Michelle, Zelterman, Daniel, Bindra, Ranjit, Sweasy, Joann B
Publicado 2018

Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?

por Zeidan, Amer M., Stahl, Maximilian, DeVeaux, Michelle, Giri, Smith, Huntington, Scott, Podoltsev, Nikolai, Wang, Rong, Ma, Xiaomei, Davidoff, Amy J., Gore, Steven D.
Publicado 2018

REGN1908‐1909 monoclonal antibodies block Fel d 1 in cat allergic subjects: Translational pharmacokinetics and pharmacodynamics

por Kamal, Mohamed A., Dingman, Robert, Wang, Claire Q., Lai, Ching‐Ha, Rajadhyaksha, Manoj, DeVeaux, Michelle, Orengo, Jamie M., Radin, Allen, Davis, John D.
Publicado 2021

Cat allergen exposure in a naturalistic exposure chamber: A prospective observational study in cat‐allergic subjects

por Yang, William H., Kelly, Suzanne, Haya, Laura, Mehri, Rym, Ramesh, Divya, DeVeaux, Michelle, Wang, Claire Q., Meier, Pretty, Narula, Sumit, Shawki, Furat, Pennington, Ryan, Perlee, Lorah, O’Brien, Meagan P.
Publicado 2022

Clinical and immunological evaluation of cat‐allergic asthmatics living with or without a cat

por Wambre, Erik R., Farrington, Mary, Bajzik, Veronique, DeBerg, Hannah A., Ruddy, Marcella, DeVeaux, Michelle, Meier, Pretty, Robinson, David, Cantor, Matt, Huang, Chengrui, Orengo, Jamie M., Wang, Claire Q., Radin, Allen
Publicado 2021

Passive Prophylactic Administration with a Single Dose of Anti–Fel d 1 Monoclonal Antibodies REGN1908–1909 in Cat Allergen–induced Allergic Rhinitis: A Randomized, Double-Blind, Pl...

por Shamji, Mohamed H., Singh, Iesha, Layhadi, Janice A., Ito, Constance, Karamani, Angeliki, Kouser, Lubna, Sharif, Hanisah, Tang, Jiaqian, Handijiev, Sava, Parkin, Rebecca V., Durham, Stephen R., Kostic, Ana, Orengo, Jamie M., DeVeaux, Michelle, Kamal, Mohamed, Stahl, Neil, Yancopoulos, George D., Wang, Claire Q., Radin, Allen R.
Publicado 2021

Identifying treatment options for BRAF(V600) wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial

por LoRusso, Patricia M., Sekulic, Aleksandar, Sosman, Jeffrey A., Liang, Winnie S., Carpten, John, Craig, David W., Solit, David B., Bryce, Alan H., Kiefer, Jeffrey A., Aldrich, Jessica, Nasser, Sara, Halperin, Rebecca, Byron, Sara A., Pilat, Mary Jo, Boerner, Scott A., Durecki, Diane, Hendricks, William P. D., Enriquez, Daniel, Izatt, Tyler, Keats, Jonathan, Legendre, Christophe, Markovic, Svetomir N., Weise, Amy, Naveed, Fatima, Schmidt, Jessica, Basu, Gargi D., Sekar, Shobana, Adkins, Jonathan, Tassone, Erica, Sivaprakasam, Karthigayini, Zismann, Victoria, Calvert, Valerie S., Petricoin, Emanuel F., Fecher, Leslie Anne, Lao, Christopher, Eder, J. Paul, Vogelzang, Nicholas J., Perlmutter, Jane, Gorman, Mark, Manica, Barbara, Fox, Lisa, Schork, Nicholas, Zelterman, Daniel, DeVeaux, Michelle, Joseph, Richard W., Cowey, C. Lance, Trent, Jeffrey M.
Publicado 2021